Our areas of partnering interest
Home / Partnering / Our areas of partnering interest
Are you wondering whether your novel science or technology may be of interest to AstraZeneca?
Here is a summary of the key areas in which we are keen to explore collaboration opportunities.
-
Oncology
-
Cardiovascular, Renal and Metabolism
-
Respiratory & Immunology
-
Vaccines and Immune Therapies
-
Precision Medicine
-
Enabling technologies
Oncology
We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Thinking differently: how AstraZeneca finds value in the competitive oncology sector through industry-leading dealmaking
Cardiovascular, Renal and Metabolism
Our bold ambition is to stop, reverse and cure CVRM diseases by maximising our medicines, delivering innovative solutions, and advancing our pipeline.
Respiratory & Immunology
We are committed to transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases. Our portfolio of inhaled and biologic medicines, and our pipeline for the future, seek to address the challenges and vast unmet medical needs patients face today.
Vaccines and Immune Therapies
We are committed to developing and delivering transformative vaccines and antibodies, providing long lasting immunity for millions of people, where the burden of disease is greatest.
Precision Medicine
More than 90 percent of our clinical pipeline now follows a precision medicine approach. We collaborate with a wide range of partners to validate and develop diagnostic devices to regulatory standards globally, and to commercialise innovative biomarker capabilities for patient selection, disease identification and drug response. These collaborations cover a broad range of cutting-edge technologies, such as tumour tissue diagnostics, molecular tests, and point-of-care diagnostics.
Enabling technologies
We are interested in cutting-edge technologies to enhance the quality, effectiveness and productivity of our research and translational capabilities.
Collaboration opportunities in China, Japan and other international markets
No matter where in the world you may be located, we are interested in exploring leading-edge collaboration opportunities with you – across our main therapy areas and beyond. We carefully consider local medical circumstances and adopt a flexible approach that enables us to meet specific patient needs in key markets.
In China, for example, we are exploring opportunities that support and enhance our existing commercial strength. Our focus is on partnering opportunities from R&D through commercial launch stage, in areas such as paediatric, nebulised, pulmonary, gastric, cardiovascular, and traditional Chinese medicine.
In Japan, we are looking to collaborate with a range of experts to help transform medical practice and patients’ lives. We focus on opportunities at or near commercial launch stage in the areas of oncology; cardiovascular, renal and metabolism; and respiratory and immunology.
Our interest goes beyond pharmaceutical products to diagnostics, devices, and digital technologies. We aim to work with a range of partners to build end-to-end patient solutions that help improve disease awareness, diagnosis, treatment and post-treatment care. While these partnerships are designed to meet the unmet medical needs of local patients, some also have potential to benefit patients globally.
Using our presence and reach, we can also help you commercialise your product in China, Japan and other international markets. Together with the China International Capital Corporation (CICC), we established the AstraZeneca-CICC Healthcare Investment Fund, a private equity fund that promotes the development of medical and healthcare innovation in China by investing in fields such as medicine and biotechnology, diagnostics, medical devices and digital health.
Veeva ID: Z4-49876
Date of preparation: November 2022